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Nitric oxide in uremia: Effects of several potentially toxic gua- levels up to 65 nmol/g tissue and MG levels up to 10
nidino compounds. Vascular and neurologic impairment re- nmol/g tissue [4].
main an important source of morbidity in patients with chronic In addition, several authors reported accumulation ofrenal failure (CRF). A portion of CRF patients still suffers
asymmetric- (ADMA), and symmetric (SDMA) dimeth-from uremic encephalopathy or other signs of nervous system
ylarginine. Increases of ADMA in blood ranged fromimpairment. Several reports demonstrate increased incidence
of cardiac infarction and cerebrovascular accidents in CRF two- to eightfold. Accumulation of L-monomethylargi-
patients, even in those with otherwise adequate dialysis treat- nine (L-NMMA) is still debated, and several observa-
ment [1]. Premature vascular disease, including myocardial tions, ours included, indicated that this substance does not
infarction, stroke, and peripheral vascular disorder, are the
accumulate in uremia. Notably, ADMA and L-NMMA,leading causes of death in this population. Although several
but not SDMA, were found to inhibit NOS.traditional risk factors for vascular disease and endothelial
dysfunction, including smoking, diabetes, dyslipidemia, and hy-
pertension, are often increased in CRF, these factors can only
METHYLGUANIDINE, GUANIDINOSUCCINICpartly explain the high vasculopathy-related morbidity and
mortality. Several authors have postulated that CRF-associated ACID, AND NITRIC OXIDE METABOLISM
atherosclerosis and endothelial dysfunction result from accu- Intravenous administration of MG in rats increasedmulation of certain ‘uremic factors,’ the identities of which are
arterial blood pressure, which was antagonized by L-argi-still a matter of debate. These factors include a variety of
nine administration [5]. Plasma concentrations were notguanidino compounds (GCs), which have been shown to be
nitric oxide synthase (NOS) modulators both in vitro and in determined in this study, but theoretical calculations sug-
vivo. However, other effects of accumulated uremic GCs have gest levels exceeding the pathobiochemical concentra-
been identified. tions. The observed EC50 for MG for the relaxation of
the rat aorta, however, was only about 1.5 M [6]. GSA
was repeatedly demonstrated to accumulate in blood,GUANIDINO COMPOUNDS IN UREMIA
CSF, and in the brain of CRF patients, and its effectsProduced as a result of protein and amino acid metab-
on nitric oxide (NO) metabolism and neuroexcitatoryolism, specific GCs were found to accumulate in biologic
actions have been shown [2]. GSA stimulated NO releasefluids and tissues of uremic patients. Their levels have
from cultured endothelial cells [7], and in rat aortic rings,been determined in serum, urine, and cerebrospinal fluid
GSA displayed a vasodilatory effect (EC50  8 M),(CSF) of nondialyzed and dialyzed renal insufficient pa-
accompanied by cGMP production, and inhibited bytients. The four highly increased compounds, which we
NOS antagonists [6]. Aoyagi et al [7] suggested thatconsequently called uremic GCs [2], are creatinine (CTN),
increased NO production in the uremic brain could beguanidine (G), guanidinosuccinic acid (GSA), and meth-
related to increased GSA levels.ylguanidine (MG). In the serum of end-stage renal fail-
In experimental animals, GSA induced convulsionsure (ESRD) patients, GSA levels increase up to 27 M,
at concentrations comparable to those found in uremicwhile MG levels increase up to 2 M [3]. In CSF, GSA
patients [2]. Experiments on cultured murine neuronsand MG reached levels of 32 and 1 M, respectively. In
demonstrated GSA to inhibit responses to gamma-amino-the brain, extreme increases were observed, with GSA
butyric acid (GABA) and glycine, and identified GSA
as an endogenous NMDA receptor agonist. Our previous
work suggests that among several other uremic GCs, GSAKey words: nitric oxide, guanidino compounds, ADMA, guanidinosuc-
cinic acid, uremic toxins, cerebro- and cardiovascular complications. was the most active in blocking GABA-typeA and glycine
receptor-mediated responses. More recent applications 2003 by the International Society of Nephrology
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Fig. 1. Hypothetical model for the excitatory
and neurotoxic action of uremic retention sol-
utes on the central nervous system. The model
focuses on reported effects on GABAA recep-
tor (GABAA-R), NMDA-type glutamate re-
ceptor (NMDA-R), and voltage-gated Ca2
channel (VGCC), but may include other
neuroexcitatory effects of these solutes. The
excitatory neurotransmitter L-glutamate is re-
leased from presynaptic terminals and binds
to AMPA and NMDA receptors. GABA-
ergic interneurons provide synaptic inhibition
through activation of GABAA-R and chloride
influx (resulting in inhibitory hyperpolariza-
tion of the membrane). In the presence of
GSA or other excitatory uremic retention sol-
utes, GABAA-Rs will be blocked and NMDA
receptors (NMDA-Rs) activated, lifting the
voltage dependent block from NMDA-Rs.
Ca2 influx through NMDA-R ionophores
and VGCCs activates postsynaptic Ca2-trig-
gered events. These may include activation of
nitric oxide synthase (NOS) and postsynaptic
density-95 (PSD-95) protein, leading to nitric
oxide (NO) synthesis and anterograde NO dif-
fusion. Presynaptic effects of NO and activa-
tion of presynaptic VGCC could increase ex-
citatory glutamate release.
of patch-clamp techniques indicated that GSA acts as a from where they may pass out of the cell into the blood-
competitive antagonist at the transmitter recognition site stream. Of the three known methylarginine residues,
of the GABAA receptor. These phenomena may underlie ADMA has been studied most extensively and qualifies
the convulsive nature of GSA. However, GSA-induced as a probable uremic toxin. Under normal conditions,
clonic convulsions were antagonized by competitive and ADMA is excreted by the kidneys, and partially catabo-
noncompetitive NMDA receptor antagonists, but not by lized by dimethylarginine dimethylaminohydrolase, lead-
drugs like diazepam or phenobarbitol. GSA also potenti- ing to the formation of citrulline and dimethylamine.
ated NMDA-, but not glutamate- or kainate-evoked con- Although the optimal analytical methodology is still
vulsions, and intrahippocampal GSA injection induced debated, several high-performance liquid chromatogra-
NMDA receptor-mediated hippocampal damage in rats. phy (HPLC) methods have been developed to quantify
We propose a hypothetical mechanism for the action ADMA. ADMA has been shown to accumulate in chronic
of uremic GCs, and in particular GSA, on glutamatergic
kidney disease (CKD) and ESRD patients. A review ofneurotransmission (Fig. 1). Cumulative effects of differ-
the available data includes analytical results obtained inent GCs have been demonstrated, and MG has been
controls, CKD, HD, and PD patients (Table 1). By andshown to inhibit brain sodium-potassium ATPase. Thus,
large, levels were observed to be lower in PD than in HDevidence indicates that GSA stimulates NMDA-type
patients. In addition, several studies suggested decreasedglutamate receptors. Calcium-dependent activation of
NO production in both HD and PD patients [8–10]. Itneuronal NOS (nNOS) and subsequent NO synthesis
is unclear whether the precursor of NO, L-arginine, iscould be involved in the sustained neuroexcitatory activ-
depleted in chronic renal failure (CRF). Notably, L-argi-ity of GSA. Recent research has indicated that the post-
nine was never shown to accumulate in uremia, and somesynaptic density-95 (PSD-95) protein plays a role in link-
ing NMDA-receptor stimulation to nNOS activation. reports indicated decreased levels of this amino acid,
PSD-95 contains multiple protein-interaction domains which is considered essential in ESRD [10, 11].
that allow it to bind simultaneously to the NMDA recep- Several in vitro tests demonstrated effects of ADMA
tor and to Ca2-activated nNOS. It has been suggested on NOS activity. Vallance et al [12] reported ADMA-
that this mechanism of action could underly the neuro- induced inhibition of macrophage and vascular NOS that
excitatory and excitotoxic effects of uremic GCs, espe- was antagonized by L-arginine (ADMA concentrations:
cially GSA. 5–400 M). Faraci et al [13] showed dose-dependent
inhibition of nNOS in the cerebrum and cerebellum,
ADMA AS A POSSIBLE UREMIC TOXIN with IC50 values of approximately 2 M. In addition,
there is substantial ex vivo evidence supporting the in-Catabolism of proteins containing methylated arginine
residues releases free methylarginines into the cytosol, fluence of ADMA on NO synthesis. ADMA enhanced
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Table 1. ADMA concentrations in control, nondialyzed and dialyzed patients with renal insufficiency
ADMA lmol/L
Control Nondialyzed patients Patients on PD Patients on HD
Vallance et al [12]a 1.150.13 – 8.70.7
N  6 N  9
MacAllister et al [11] 0.360.09 – 0.90.1
N  9 N  9
Anderstam et al [18] 0.360.08 0.700.27 0.590.22
N  9 N  11 N  19
Marescau et al [3] 0.410.09 0.800.14 – –
N  66 N  38
Kielstein et al [8] 1.00.1 2.10.4 6.00.5
N  37 N  37 N  43
Schmidt et al [9] 0.400.08 – 4.140.78
N  13 N  17
Schmidt et al [10] 0.400.08 2.160.27 –
N  11 N  11
Kang et al [19] Traces – 82
N  10 N  10
Kielstein et al [20] 1.40.7 4.20.9 – –
N  44 N  16
a Values reported by Vallance et al are total dimethylarginine levels (ADMASDMA)
the tone in rat aortic rings (EC50  26 M) [12], and centrations found in patients: (1) EC50 or IC50 levels
increased tension in human middle cerebral artery rings should not necessarily be reached in order to obtain
without endothelium (EC50  16 M) [14]. In addition, pathophysiologically relevant effects; (2) tissue ADMA
ADMA inhibited acetylcholine-induced relaxation (EC50 concentrations have been shown to be higher than circu-
 54 M), which was antagonized by L-arginine. Finally, lating ADMA concentrations [17], and ADMA may ac-
MacAllister et al [15] demonstrated ADMA-induced in- cumulate in regenerated endothelial cells; and (3) in-
hibition of endothelium-dependent relaxation in human termutual influences may exist among various solutes in
saphenous veins (EC50  18 M). the uremic milieu as cumulative, and/or synergistic ef-
In vivo experiments in guinea pigs indicated increases fects have been shown for candidate uremic toxins (in-
of arterial blood pressure by ADMA (10 M). In humans, cluding GCs).
local infusion of ADMA in the brachial artery induced
an increase in forearm blood flow, again antagonized by
CONCLUSIONL-arginine. Moreover, Faraci et al [13] demonstrated in
Several GCs have been shown consistently to accumu-anesthesized rats that ADMA (10 M) constricted the
late in biological fluids and tissues of renal insufficientbasilar artery by 9%, and inhibited acetylcholine-pro-
patients (these include G, MG, CTN, GSA, ADMA,duced vasodilation. Most interestingly, high concentra-
and SDMA). MG was found to stimulate endothelium-tions of ADMA have been shown to correlate with
dependent vasodilation and inhibit neuronal responsescardio- and cerebrovascular symptomatology in uremic
to GABA and glycine. We propose GSA as a possibleindividuals. Hemodialysis patients with atherosclerotic
uremic toxin, contributing to central nervous system (ex-disease had higher ADMA levels than those without (i.e.,
citotoxic) phenomena. GSA was shown to induce endo-7 vs. 4 M) [8]. Recent observations in hemodialyzed
thelial NOS (eNOS) in a dose-dependent manner. Inpatients indicated plasma ADMA levels to be the second
addition, the convulsant effect of GSA might be due tofactor predicting overall mortality and cardiovascular
events (median plasma ADMA 2.5 M) [16]. inhibition of neuronal GABA/glycine responses, and/or
potent and specific agonistic effects at NMDA receptors.In order to meet all criteria of a true uremic toxin,
one should, in addition, demonstrate that concentrations NMDA receptor activation by GSA will most probably
contribute to its neurotoxicity, as demonstrated by hip-in studies showing biological activities conform with
those found in body fluids or tissues of uremic subjects. pocampal cell loss in rats. However, GSA accumulation
in biological fluids and brain tissue still has to be corre-This seems indeed the case for ADMA, as two- to eight-
fold increases of ADMA were found in body fluids (up lated with neurologic uremic complications.
We propose ADMA as a probable uremic toxin, con-to 8 M). These levels are comparable to some of the
concentrations used to demonstrate in vitro, ex vivo, and tributing to cardio- and cerebrovascular complications
in uremia. ADMA has been shown to accumulate inin vivo effects of ADMA. However, there are several
caveats when comparing those concentrations with con- CRF, irrespective of treatment, and concentrations up
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in serum and urine of nondialyzed patients with chronic renalto 8 M have been reported. Optimal analytical method-
insufficiency. Metabolism 46:1024–1031, 1997
ology is still being debated, but reported concentrations 4. De Deyn PP, Marescau B, D’Hooge R, et al: Guanidino compound
levels in brain regions of non-dialyzed uremic patients. Neurochemare comparable with those shown to exert toxic effects
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